Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Conditions
Interventions
APL-5125
Locations
9
United States
City of Hope
Duarte, California, United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
Duke Cancer Institute
Durham, North Carolina, United States
Carolina BioOncology Institute
Huntersville, North Carolina, United States
Start Date
June 18, 2024
Primary Completion Date
April 1, 2027
Completion Date
May 1, 2027
Last Updated
January 7, 2026
NCT07446322
NCT02600949
NCT05919264
NCT04891289
NCT07541924
NCT05969860
Lead Sponsor
Apollo Therapeutics Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions